{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:22:01Z","timestamp":1785543721933,"version":"3.56.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.semnephrol.2018.05.023","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T18:13:46Z","timestamp":1535739226000},"page":"531-540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Treatment of IgA Nephropathy: Evolution Over Half a Century"],"prefix":"10.1016","volume":"38","author":[{"given":"Jonathan","family":"Barratt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney C.W.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2018.05.023_bib0001","article-title":"Non-immunosuppressive treatment for IgA nephropathy","volume":"3","author":"Reid","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0002","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1742-1241.2009.02038.x","article-title":"ACEI\/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials","volume":"63","author":"Cheng","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0003","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/1470320313515036","article-title":"ACE insertion\/deletion polymorphism (rs1799752) modifies the renoprotective effect of renin-angiotensin system blockade in patients with IgA nephropathy","volume":"16","author":"Teranishi","year":"2015","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0004","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ndt\/gfr349","article-title":"Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study","volume":"27","author":"Tang","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0005","doi-asserted-by":"crossref","first-page":"e62736","DOI":"10.1371\/journal.pone.0062736","article-title":"The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy\u2013a randomized cross-over study","volume":"8","author":"Szeto","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0006","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1056\/NEJM199411033311804","article-title":"A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group","volume":"331","author":"Donadio","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0007","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/ndt\/gfn454","article-title":"Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial","volume":"24","author":"Ferraro","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0008","first-page":"71","article-title":"Abnormalities of glycogenes in tonsillar lymphocytes in IgA nephropathy","volume":"72","author":"Inoue","year":"2011","journal-title":"Adv Otorhinolaryngol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0009","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/ndt\/gfq674","article-title":"A meta-analysis of the clinical remission rate and long-term efficacy of tonsillectomy in patients with IgA nephropathy","volume":"26","author":"Wang","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0010","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/ndt\/gfu020","article-title":"A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy","volume":"29","author":"Kawamura","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0011","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.ajkd.2014.06.036","article-title":"Tonsillectomy for IgA nephropathy: a meta-analysis","volume":"65","author":"Liu","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0012","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000441852","article-title":"Tonsillectomy in a European cohort of 1,147 patients with IgA nephropathy","volume":"132","author":"Feehally","year":"2016","journal-title":"Nephron"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0013","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/ki.2012.280","article-title":"The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines\u2013application to the individual patient","volume":"82","author":"Radhakrishnan","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0014","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0015","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0016","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1681\/ASN.2017060713","article-title":"Effects of two immunosuppressive treatment protocols for IgA nephropathy","volume":"29","author":"Rauen","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0017","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","article-title":"Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy","volume":"66","author":"Hogg","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0018","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","article-title":"Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial","volume":"69","author":"Hou","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0019","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial","volume":"15","author":"Pozzi","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0020","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1681\/ASN.V131142","article-title":"Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy","volume":"13","author":"Ballardie","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0021","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/ndt\/gfw284","article-title":"Moderator's view: treatment of IgA nephropathy-getting comfortable with uncertainty","volume":"31","author":"Glassock","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0022","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/ndt\/gfw285","article-title":"Pro: STOP immunosuppression in IgA nephropathy?","volume":"31","author":"Pozzi","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0023","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0024","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments","volume":"86","author":"Coppo","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0025","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1523-1755.2005.00460.x","article-title":"Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy","volume":"68","author":"Tang","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0026","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ki.2009.499","article-title":"Long-term study of mycophenolate mofetil treatment in IgA nephropathy","volume":"77","author":"Tang","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0027","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00467-017-3652-1","article-title":"The gut-kidney axis in IgA nephropathy: role of microbiota and diet on genetic predisposition","volume":"33","author":"Coppo","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0028","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/ki.1986.274","article-title":"Sequential study of the IgA system in relapsing IgA nephropathy","volume":"30","author":"Feehally","year":"1986","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0029","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1681\/ASN.2006060658","article-title":"O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy","volume":"17","author":"Smith","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2249.1994.tb06011.x","article-title":"Low antibody affinity restricted to the IgA isotype in IgA nephropathy","volume":"95","author":"Layward","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0031","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ng.787","article-title":"Genome-wide association study identifies susceptibility loci for IgA nephropathy","volume":"43","author":"Gharavi","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0032","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.krcp.2016.09.001","article-title":"Diagnosis and treatment of patients with IgA nephropathy in Japan","volume":"35","author":"Tomino","year":"2016","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0033","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.2016050496","article-title":"Toll-like receptor 9 stimulation induces aberrant expression of a proliferation-inducing ligand by tonsillar germinal center B cells in IgA nephropathy","volume":"28","author":"Muto","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0034","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev.immunol.21.120601.141126","article-title":"Toll-like receptors","volume":"21","author":"Takeda","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0035","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-2249.2008.03855.x","article-title":"CpG-oligodeoxynucleotides stimulate immunoglobulin A secretion in intestinal mucosal B cells","volume":"155","author":"Blaas","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0036","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/ndt\/gfm781","article-title":"External suppression causes the low expression of the Cosmc gene in IgA nephropathy","volume":"23","author":"Qin","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0037","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ncprheum0292","article-title":"Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling","volume":"2","author":"Kyburz","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0038","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s11255-017-1574-2","article-title":"Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy","volume":"49","author":"Gao","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0039","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1172\/JCI45563","article-title":"Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy","volume":"121","author":"McCarthy","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0040","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clim.2007.11.003","article-title":"Increase in B-cell-activation factor (BAFF) and IFN-gamma productions by tonsillar mononuclear cells stimulated with deoxycytidyl-deoxyguanosine oligodeoxynucleotides (CpG-ODN) in patients with IgA nephropathy","volume":"126","author":"Goto","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0041","article-title":"Oral budesonide for induction of remission in ulcerative colitis","volume":"10","author":"Sherlock","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0042","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1093\/ndt\/gfr052","article-title":"New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria","volume":"26","author":"Smerud","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0043","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstrom","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0044","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nrneph.2017.65","article-title":"Glomerular disease: targeted steroid therapy for IgA nephropathy","volume":"13","author":"Glassock","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0045","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0046","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.4049\/jimmunol.1102603","article-title":"Spleen tyrosine kinase is important in the production of proinflammatory cytokines and cell proliferation in human mesangial cells following stimulation with IgA1 isolated from IgA nephropathy patients","volume":"189","author":"Kim","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0047","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ki.2008.636","article-title":"The ubiquitin-proteasome pathway and IgA nephropathy: a novel link?","volume":"75","author":"Tang","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0048","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/ki.1997.171","article-title":"Activated complement C3: a potentially novel predictor of progressive IgA nephropathy","volume":"51","author":"Zwirner","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0049","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1681\/ASN.2014101000","article-title":"Current understanding of the role of complement in IgA nephropathy","volume":"26","author":"Maillard","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0050","first-page":"335","article-title":"Glomerular deposition and serum levels of complement control proteins in patients with IgA nephropathy","volume":"21","author":"Miyazaki","year":"1984","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0051","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1053\/ajkd.2001.28611","article-title":"Mesangial IgA2 deposits and lectin pathway-mediated complement activation in IgA glomerulonephritis","volume":"38","author":"Hisano","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0052","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2215\/CJN.09710913","article-title":"Association of C4d deposition with clinical outcomes in IgA nephropathy","volume":"9","author":"Espinosa","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0053","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1681\/ASN.2005090923","article-title":"Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease","volume":"17","author":"Roos","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0054","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.4049\/jimmunol.167.5.2861","article-title":"Human IgA activates the complement system via the mannan-binding lectin pathway","volume":"167","author":"Roos","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/oxfordjournals.ndt.a092269","article-title":"The role of complement in mesangial cell damage","volume":"8","author":"Hansch","year":"1993","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0056","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1523-1755.1998.00961.x","article-title":"Expression of decay accelerating factor mRNA and complement C3 mRNA in human diseased kidney","volume":"54","author":"Abe","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0057","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1681\/ASN.2014010096","article-title":"Variants in complement factor H and complement factor h-related protein genes, CFHR3 and CFHR1, affect complement activation in IgA nephropathy","volume":"26","author":"Zhu","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0058","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1681\/ASN.2015111210","article-title":"Fine mapping implicates a deletion of CFHR1 and CFHR3 in protection from IgA nephropathy in Han Chinese","volume":"27","author":"Xie","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0059","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/ckj\/sfv076","article-title":"Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum?","volume":"8","author":"Ring","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0060","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.05.023_bib0061","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/nchembio.2208","article-title":"Small-molecule factor D inhibitors targeting the alternative complement pathway","volume":"12","author":"Maibaum","year":"2016","journal-title":"Nat Chem Biol"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929518300858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929518300858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T11:48:42Z","timestamp":1717242522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929518300858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0270929518300858"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2018.05.023","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of IgA Nephropathy: Evolution Over Half a Century","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2018.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}